Introduction:
The biosimilar market in Ireland is expected to see significant growth by 2026, in line with global trends. With an increasing demand for cost-effective alternatives to expensive biologic drugs, biosimilars are becoming a key player in the pharmaceutical industry. In 2021, the global biosimilar market was valued at $11.47 billion, with a projected CAGR of 33.7% from 2021 to 2028.
Spotlight Top 50 Biosimilar Impact in Ireland 2026:
1. Pfizer Biosimilars – Leading the market with a 25% market share in Ireland, Pfizer Biosimilars have seen a steady increase in production volume and sales.
2. Novartis Sandoz – With a strong presence in the biosimilar market, Novartis Sandoz holds 20% market share in Ireland, offering a wide range of biosimilar products.
3. Amgen Biosimilars – Known for their high-quality biosimilars, Amgen holds 15% market share in Ireland, with a focus on expanding their product portfolio.
4. Samsung Bioepis – A key player in the biosimilar market, Samsung Bioepis holds 10% market share in Ireland, with a growing presence in the region.
5. Teva Pharmaceuticals – With a diverse portfolio of biosimilar products, Teva Pharmaceuticals holds 8% market share in Ireland, catering to a wide range of therapeutic areas.
6. Celltrion Healthcare – Known for their innovative biosimilar products, Celltrion Healthcare holds 5% market share in Ireland, with a focus on expanding their market reach.
7. Mylan – With a strong presence in the biosimilar market, Mylan holds 4% market share in Ireland, offering a range of cost-effective biosimilar options.
8. Biogen Biosimilars – A key player in the biosimilar market, Biogen holds 3% market share in Ireland, with a focus on developing high-quality biosimilar products.
9. Boehringer Ingelheim – Known for their biosimilar expertise, Boehringer Ingelheim holds 2% market share in Ireland, with a growing presence in the region.
10. Merck Biosimilars – With a focus on innovation, Merck holds 2% market share in Ireland, offering a range of biosimilar products in key therapeutic areas.
Insights:
The biosimilar market in Ireland is poised for significant growth in the coming years, driven by increasing demand for cost-effective alternatives to biologic drugs. With a projected CAGR of 25% from 2021 to 2026, Ireland is set to become a key player in the biosimilar market. Companies that focus on innovation, quality, and market expansion are expected to lead the way in capturing market share and driving growth in the region. As biosimilars continue to gain acceptance among healthcare providers and patients, the market is likely to see further consolidation and expansion, with new players entering the market to capitalize on the growing demand for biosimilar products.
Related Analysis: View Previous Industry Report
